Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Forest Labs Sues Several Companies For Infringement Of BYSTOLIC Patent

3/14/2012 11:58 AM ET

Forest Laboratories, Inc. (FRX: Quote) and Forest Laboratories Holdings, Ltd. said Wednesday that they and Janssen Pharmaceutica NV have jointly filed a lawsuit in the U.S. District Court for the District of Delaware against several companies for infringement of U.S. Patent No. 6,545,040, relating to Forest's BYSTOLIC product.

Forest licenses the '040 patent from Janssen. The '040 patent expires in December 2021, including patent term extension.

The defendants named in the lawsuit include Amerigen Pharmaceuticals, Inc., Glenmark Generics, Inc., Hetero USA Inc., Torrent Pharmaceuticals Ltd., Watson Laboratories, Inc., and related companies and subsidiaries thereof.

Janssen and Forest also filed a lawsuit in the U.S. District Court for the Northern District of Illinois against Alkem Laboratories Limited and Indchemie Health Specialties Pvt. Ltd for infringement of the '040 patent.

Janssen and Forest received notification from those companies that they had filed Abbreviated New Drug Applications with Paragraph IV certifications seeking approval to market generic versions of BYSTOLIC before the expiration of the '040 patent. The lawsuits were commenced before the expiration of forty-five days from the date of receipt of each notification letter.

Register
To receive FREE breaking news email alerts for Forest Laboratories Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Justin Moore has been named Humanitarian of the Year by by the Armed Forces Foundation. Moore received the award alongside Big Machine Label Group President/CEO Scott Borchetta for their service and commitment to the morale and welfare of military families through the Crown Royal "Your Hero's Name Here" contest. International Business Machines Corp. said Wednesday after the markets closed that its first quarter profit fell 21% from last year, hurt by lower revenue as well as a hefty workforce rebalancing charge. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Stocks moved sharply higher over the course of the trading day on Wednesday, further offsetting the steep losses posted late last week. The markets benefited from a positive reaction to the latest earnings news as well as remarks by Federal Reserve Chairman Janet Yellen. The major averages saw further upside going into the close, ending the session at their best levels of the day.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.